In the News

413 News Items found
Leiomyosarcoma expert Martee Hensley
In the Clinic
What’s New in Leiomyosarcoma?
In this Q&A, medical oncologist Martee Hensley discusses the diagnosis and treatment of leiomyosarcoma and other uterine sarcomas.
Rihanna sitting in a chair outside
Feature
Getting to the Root of Pediatric Cancers
MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.
Pattie Fuller smiles while wearing a pink plaid poncho
After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
Fluorescent image of CAR T cells in mouse liver fibrosis
In the Lab
From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.
Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.
Dr. Geoffrey Ku
For patients who are newly diagnosed with gastroesophageal adenocarcinoma, the most common type of stomach and esophageal cancer, the FDA has approved zanidatamab as an additional medication for those who are getting chemotherapy.
Close up of an MSK researcher's hands and arms handling test tubes in the lab.
Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Announcement
Seven students will be awarded PhD degrees on May 19, 2021, from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), an innovative doctoral program that prepares the next generation of basic laboratory scientists to work in research areas related to human disease with a focus on cancer.
Dr. Sandra D'Angelo
In the Clinic
The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.
A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.